AstraZeneca PLC (NASDAQ:AZN) Position Trimmed by Dakota Wealth Management

Dakota Wealth Management cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,763 shares of the company’s stock after selling 317 shares during the quarter. Dakota Wealth Management’s holdings in AstraZeneca were worth $1,384,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its stake in shares of AstraZeneca by 17.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after purchasing an additional 9,002,450 shares during the period. Capital World Investors raised its position in shares of AstraZeneca by 0.3% during the first quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after purchasing an additional 29,497 shares during the period. Envestnet Asset Management Inc. raised its holdings in AstraZeneca by 16.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after buying an additional 488,644 shares during the period. Clearbridge Investments LLC raised its holdings in shares of AstraZeneca by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after acquiring an additional 186,010 shares during the period. Finally, Fayez Sarofim & Co lifted its holdings in shares of AstraZeneca by 4.7% in the first quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock valued at $202,588,000 after purchasing an additional 134,784 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Down 1.1 %

AstraZeneca stock opened at $75.05 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The firm has a market capitalization of $232.69 billion, a PE ratio of 36.79, a P/E/G ratio of 1.43 and a beta of 0.46. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company’s 50-day moving average is $80.40 and its 200-day moving average is $78.51.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the previous year, the firm earned $1.08 earnings per share. AstraZeneca’s revenue for the quarter was up 9.1% compared to the same quarter last year. Sell-side analysts anticipate that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research analyst reports. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. TD Cowen lifted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.